GlaxoSmithKline (GSK) will be providing certain distribution support services for an interim period. The agreement also marks the start of a strategic relationship with GSK whereby Paladin Labs will have the first right to partner with GSK on a number of products that GSK may choose to license or divest in Canada. Financial terms of the transaction were not disclosed.
Dexedrine is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) and in the adjunctive treatment of narcolepsy.
Jonathan Goodman, president and CEO of Paladin Labs, said: This agreement will allow us to add to our portfolio of specialty pharmaceutical products and to build significant critical mass for our organization. Not only will we be adding close to $14 million to our top line next year, but just as importantly, we are establishing a strategic relationship with GSK for potential future transactions like this one.